The 68Ga-labeled NGR peptide PET radiotracer successfully monitored anti-cancer treatment efficacy in vivo by tracking changes in tumor APN/CD13 receptor expression, with bestatin treatment reducing both tumor growth and radiotracer uptake.
Real-time treatment monitoringNGR peptide PET scans detected molecular changes in tumors during treatment — enabling assessment of whether anti-cancer drugs are working before waiting for tumor size changes
What the researchers found
Bestatin treatment reduced tumor growth and 68Ga-NODAGA-c(NGR) PET uptake in HT1080 and B16-F10 tumors. The NGR peptide radiotracer specifically detected APN/CD13 expression changes, enabling in vivo monitoring of antiangiogenic treatment efficacy.
Why it matters
Currently, treatment response is often assessed weeks later by measuring tumor size. A peptide-based PET scan that detects molecular changes in real-time could enable doctors to switch ineffective treatments earlier, improving patient outcomes.
The numbers in context
Bestatin 15 mg/kg 7d; actinonin 5 mg/kg 7d; 5.5 MBq 68Ga-NODAGA-c(NGR); significantly lower uptake after bestatin (p≤0.05 HT1080, p≤0.01 B16-F10)
How the study worked
In vivo study. HT1080 and B16-F10 tumor-bearing mice treated with bestatin (15 mg/kg) or actinonin (5 mg/kg) IP × 7 days. PET scans on days 5 and 10 using 5.5 MBq 68Ga-NODAGA-c(NGR). Ex vivo biodistribution. Western blot for APN/CD13.
Who was studied
SCID mice with subcutaneous HT1080 or B16-F10 tumors
What this study cannot tell us
Mouse subcutaneous tumor models. Actinonin showed inconsistent results between tumor types. Clinical translation of 68Ga-NGR PET needs human validation. APN/CD13 expression varies between human cancers.
How to read the evidence
Moderate evidence: in vivo imaging study with two tumor models, quantitative PET data, and molecular validation by Western blot.
When this study was published
Published 2021. Peptide-based PET imaging continues advancing toward clinical oncology applications.
The bigger picture
Peptide-based molecular imaging is becoming a standard tool in precision oncology. The ability to monitor treatment at the molecular level — before tumor shrinkage is visible — represents a paradigm shift in cancer management.
Questions still open
- Could NGR peptide PET scans be used clinically to guide antiangiogenic cancer therapy?
- Would this approach work for monitoring anti-VEGF drugs like bevacizumab?
- Can the NGR peptide be modified for therapeutic delivery as well as imaging?
Common questions
How does a peptide PET scan work?
Why is this better than regular imaging?
Read the original research
In Vivo Molecular Imaging of the Efficacy of Aminopeptidase N (APN/CD13) Receptor Inhibitor Treatment on Experimental Tumors Using 68Ga-NODAGA-c(NGR) Peptide.
BioMed research international, 2021, 6642973
Citation
Kis, Adrienn; Dénes, Noémi; Szabó, Judit P; Arató, Viktória; Beke, Lívia; Matolay, Orsolya; Enyedi, Kata Nóra; Méhes, Gábor; Mező, Gábor; Bai, Péter; Kertész, István; Trencsényi, György. (2021). In Vivo Molecular Imaging of the Efficacy of Aminopeptidase N (APN/CD13) Receptor Inhibitor Treatment on Experimental Tumors Using 68Ga-NODAGA-c(NGR) Peptide.. BioMed research international, 2021, 6642973. https://doi.org/10.1155/2021/6642973